Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 09:04 pm
Share
Spero Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 2.01 million compared to USD 3.06 million a year ago. Net loss was USD 11.68 million compared to USD 22.52 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.7 a year ago.
For the nine months, revenue was USD 6.07 million compared to USD 15.51 million a year ago. Net loss was USD 73.19 million compared to USD 60.52 million a year ago. Basic loss per share from continuing operations was USD 2.16 compared to USD 1.99 a year ago.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.